載入...
Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second‐generation, enhanced‐selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B‐cell non−Hodgkin lymphoma (B‐cell NHL) and chronic lympho...
Na minha lista:
| 發表在: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6500982/ https://ncbi.nlm.nih.gov/pubmed/30815927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13983 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|